{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:07:05Z","timestamp":1786118825412,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1097\/pai.0b013e318223ef29","type":"journal-article","created":{"date-parts":[[2011,7,16]],"date-time":"2011-07-16T10:02:19Z","timestamp":1310810539000},"page":"41-46","source":"Crossref","is-referenced-by-count":12,"title":["The Number of Lymphoma-associated Macrophages in Tumor Tissue Is an Independent Prognostic Factor in Patients With Follicular Lymphoma"],"prefix":"10.1097","volume":"20","author":[{"given":"Bosko","family":"Andjelic","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biljana","family":"Mihaljevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Milena","family":"Todorovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Bila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ljubomir","family":"Jakovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja Perunicic","family":"Jovanovic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-8-20210126","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1200\/JCO.2005.07.019","article-title":"Treatment strategies in follicular lymphomas: current status and future perspectives.","volume":"23","author":"Hiddemann","year":"2005","journal-title":"J Clin Oncol"},{"key":"R3-8-20210126","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/S0046-8177(87)80035-7","article-title":"Mitotic counts in follicular lymphomas.","volume":"18","author":"Ellison","year":"1987","journal-title":"Hum Pathol"},{"key":"R4-8-20210126","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/bjc.1987.41","article-title":"Mitotic activity in non-Hodgkins lymphoma. Relation to the Kiel classification and to prognosis.","volume":"55","author":"Akerman","year":"1987","journal-title":"Br J Cancer"},{"key":"R5-8-20210126","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1182\/blood.V85.12.3671.bloodjournal85123671","article-title":"Prognostic value of cellular proliferation and histologic grade in follicular lymphoma.","volume":"85","author":"Martin","year":"1995","journal-title":"Blood"},{"key":"R6-8-20210126","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1182\/blood-2002-07-2298","article-title":"A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival.","volume":"101","author":"Hans","year":"2003","journal-title":"Blood"},{"key":"R7-8-20210126","doi-asserted-by":"crossref","first-page":"3806","DOI":"10.1182\/blood.V99.10.3806","article-title":"Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade.","volume":"99","author":"Ott","year":"2002","journal-title":"Blood"},{"key":"R8-8-20210126","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1200\/JCO.1991.9.5.762","article-title":"Multivariate analysis of prognostic factors in stage IV follicular low-grade lymphoma: a risk model.","volume":"9","author":"Romaguera","year":"1991","journal-title":"J Clin Oncol"},{"key":"R9-8-20210126","first-page":"783","article-title":"Prognosis of follicular lymphoma: a predictive model based on a retrospective analysis of 987 cases. Intergruppo Italiano Linfomi.","volume":"95","author":"Federico","year":"2000","journal-title":"Blood"},{"key":"R10-8-20210126","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index.","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"R11-8-20210126","doi-asserted-by":"crossref","first-page":"4555","DOI":"10.1200\/JCO.2008.21.3991","article-title":"Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project.","volume":"27","author":"Federico","year":"2009","journal-title":"J Clin Oncol"},{"key":"R12-8-20210126","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"R13-8-20210126","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood-2004-06-2298","article-title":"Gene expression profiling in follicular lymphoma to assess clinical aggressiveness and to guide the choice of treatment.","volume":"105","author":"Glas","year":"2005","journal-title":"Blood"},{"key":"R14-8-20210126","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1182\/blood-2005-04-1565","article-title":"Analysis of multiple biomarkers shows that lymphoma-associated macrophage (LAM) content is an independent predictor of survival in follicular lymphoma (FL).","volume":"106","author":"Farinha","year":"2005","journal-title":"Blood"},{"key":"R15-8-20210126","doi-asserted-by":"crossref","first-page":"5052","DOI":"10.1200\/JCO.2006.06.4642","article-title":"Number of CD4 cells and location of forkhead box protein P3-positive cells in diagnostic follicular lymphoma tissue microarrays correlates with outcome.","volume":"24","author":"Lee","year":"2006","journal-title":"J Clin Oncol"},{"key":"R16-8-20210126","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1200\/JCO.2006.06.4766","article-title":"Immunohistochemical patterns of reactive microenvironment are associated with clinicobiologic behavior in follicular lymphoma patients.","volume":"24","author":"Alvaro","year":"2006","journal-title":"J Clin Oncol"},{"key":"R17-8-20210126","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1023\/A:1008347425795","article-title":"Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe dEtudes des Lymphomes de lAdulte.","volume":"10","author":"Coiffier","year":"1999","journal-title":"Ann Oncol"},{"key":"R18-8-20210126","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2900010209","article-title":"Criteria for the cytologic subclassification of follicular lymphomas: a proposed alternative method.","volume":"1","author":"Mann","year":"1983","journal-title":"Hematol Oncol"},{"key":"R20-8-20210126","first-page":"1860","article-title":"Report of the committee on hodgkins disease staging classification.","volume":"31","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"R21-8-20210126","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1002\/hon.772","article-title":"Prognosis of follicular lymphomas.","volume":"24","author":"Luminari","year":"2006","journal-title":"Hematol Oncol"},{"key":"R22-8-20210126","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1001\/jama.1991.03470120074036","article-title":"Cardiac toxicity 4 to 20 years after completing anthracycline therapy.","volume":"266","author":"Steinherz","year":"1991","journal-title":"JAMA"},{"key":"R23-8-20210126","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1177\/0897190008314776","article-title":"A review of the cardiovascular effects of oncology agents.","volume":"21","author":"Frei","year":"2008","journal-title":"J Pharm Pract"},{"key":"R24-8-20210126","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.imbio.2006.06.002","article-title":"Classical and alternative activation of mononuclear phagocytes: picking the best of both worlds for tumor promotion.","volume":"211","author":"Van Ginderachter","year":"2006","journal-title":"Immunobiology"},{"key":"R25-8-20210126","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa0905680","article-title":"Tumor-associated macrophages and survival in classic Hodgkins lymphoma.","volume":"362","author":"Steidl","year":"2010","journal-title":"N Engl J Med"},{"key":"R26-8-20210126","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1158\/1078-0432.CCR-07-0778","article-title":"A high tumor-associated macrophage content predicts favorable outcome in follicular lymphoma patients treated with rituximab and cyclophosphamide-doxorubicin-vincristine-prednisone.","volume":"13","author":"Taskinen","year":"2007","journal-title":"Clin Cancer Res"},{"key":"R27-8-20210126","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1200\/JCO.2007.12.8298","article-title":"High numbers of tumor-associated macrophages have an adverse prognostic value that can be circumvented by rituximab in patients with follicular lymphoma enrolled onto the GELA-GOELAMS FL-2000 trial.","volume":"26","author":"Canioni","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Applied Immunohistochemistry & Molecular Morphology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00129039-201201000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T16:50:51Z","timestamp":1786035051000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00129039-201201000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/pai.0b013e318223ef29","relation":{},"ISSN":["1541-2016"],"issn-type":[{"value":"1541-2016","type":"print"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}